GlycoFlux™ Human GXYLT1 Overexpression Glycoengineered Cell (CAT#: GLJF-0925-JF189)

Description	GlycoFlux™ human GXYLT1 overexpression glycoengineered cell is a stable cell line engineered to enhance GXYLT1 activity, which adds the first xylose to O-glucose-modified EGF repeats of proteins such as NOTCH1. As a glycoengineered model, it supports research on Notch signaling, developmental processes, and glycosylation-dependent cell fate determination.
Product Type	Overexpression Cell Lines
Cell Line	As requested by the client.

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	GXYLT1
Full Name	Glucoside xylosyltransferase 1
Alternative Name	FLJ43151; GLT8D3
Location	12q12
Gene ID	283464
Summary	Xylosyltransferase that adds the first xylose to O-glucose-modified residues in epidermal growth factor (EGF) repeats of proteins, such as NOTCH1.